<div class="NavFrame collapsed" style="float:right;   position: absolute;  top: -3em;  right:30px; width:auto; background:#eae9e9;" align="right"><div class="NavHead" style="float:right; font-size:85%; background:#dadadb; padding-right: 90px" align="right">ᱤᱸᱞᱤᱥ ᱞᱤᱸᱠ</div><div class="NavContent" style="background:#eae9e9; width:auto" align="right"><nowiki>https://or.wikipedia.org/wiki/Mirabegron</nowiki></div></div>{{Drugbox|drug_name=|IUPAC_name=2-(2-Amino-1,3-thiazol-4-yl)-''N''-[4-(2-<nowiki/>{[(2''R'')-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide|image=Mirabegron.svg|width=300

<!-- Clinical data -->|tradename=Myrbetriq, Betanis, Betmiga, others|licence_EU=yes|licence_US=Mirabegron|Drugs.com={{drugs.com|monograph|mirabegron}}|MedlinePlus=|pregnancy_AU=B3|pregnancy_US=C|pregnancy_category=|legal_AU=S4|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=POM|legal_US=Rx-only|legal_status=℞-only|routes_of_administration=By mouth ([[Tablet (pharmacy)|tablets]])

<!-- Pharmacokinetic data -->|bioavailability=29–35%<ref name = MSR/>|protein_bound=71%<ref name = MSR/>|metabolism=[[Hepatic]] via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism ''in vivo'' by [[CYP2D6]] and [[CYP3A4]]. Some involvement of butylcholinesterase<ref name = MSR/>|elimination_half-life=50 hours<ref name = MSR>{{cite web|title=mirabegron (Rx) - Myrbetriq|work=Medscape Reference|publisher=WebMD|accessdate=17 November 2013|url=http://reference.medscape.com/drug/myrbetriq-mirabegron-999757}}</ref>|excretion=Urine (55%), faeces (34%)<ref name = MSR/>

<!-- Identifiers -->|CAS_number=223673-61-8|ATCvet=|ATC_prefix=G04|ATC_suffix=BD12|PubChem=9865528|ChemSpiderID=8041219|DrugBank=|synonyms=YM-178

<!-- Chemical data -->|C=21|H=24|N=4|O=2|S=1|molecular_weight=396.506 g/mol|smiles=O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N|StdInChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1|StdInChIKey=PBAPPPCECJKMCM-IBGZPJMESA-N}}
'''ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ'''(ᱤᱸᱞᱤᱥ ᱯᱟᱹᱨᱥᱤᱛᱮ '''Mirabegron''', ᱢᱤᱫ ᱟᱹᱠᱷᱨᱤᱧ ᱧᱩᱛᱢ ᱢᱤᱨᱵᱮᱴᱨᱤᱠ/ '''Myrbetriq''') ,ᱱᱚᱣᱟ ᱢᱤᱫ ᱨᱟᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ ᱛᱤᱠᱪᱷᱟᱹᱨᱮ([[:en:overactive bladder|overactive bladder]]) ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ।<ref name="AHFS2019" /> ᱚᱠᱥᱤᱵᱭᱩᱴᱤᱱ  ([[:en:oxybutynin|oxybutynin]]) ᱞᱮᱠᱟ ᱟᱱᱴᱤᱢᱚᱥᱠᱟᱨᱤᱱ ᱨᱟᱱ ଭଳି ଆଣ୍ଟିମସ୍କାରିନିକ ଔଷଧ ([[:en:antimuscarinic medication|antimuscarinic medication]]) ᱠᱷᱚᱱ  ᱠᱚᱢᱜᱮᱠᱚ ᱯᱚᱥᱚᱸᱫᱼᱟ। <ref name="BNF76">{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=763|edition=76}}</ref>  ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱚᱪᱟ ᱨᱮᱠᱚ ᱮᱢᱚᱜᱼᱟ ।<ref name="AHFS2019">{{cite web|title=Mirabegron Monograph for Professionals|url=https://www.drugs.com/monograph/mirabegron.html|website=Drugs.com|publisher=American Society of Health-System Pharmacists|accessdate=18 March 2019|language=en}}</ref>

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ ᱨᱮᱱᱟᱜ ᱚᱨᱥᱚᱝ ᱛᱮ ᱥᱚᱠᱛᱚ ᱢᱟᱭᱟᱢ ᱪᱟᱯ , ᱵᱚᱦᱚᱜ ᱦᱟᱹᱥᱩ, ᱪᱩᱰᱩ ᱱᱟᱞᱟ ᱜᱷᱟᱣ ᱠᱚ ᱦᱩᱭ ᱫᱟᱲᱟ ᱦᱟᱜᱼᱟ ।<ref name="AHFS2019">{{cite web|title=Mirabegron Monograph for Professionals|url=https://www.drugs.com/monograph/mirabegron.html|website=Drugs.com|publisher=American Society of Health-System Pharmacists|accessdate=18 March 2019|language=en}}</ref> ᱱᱚᱣᱟ ᱵᱟᱫ ᱠᱟᱛᱮ ᱟᱧᱤᱭᱳᱭᱤᱰᱤᱢᱟ, ᱚᱦᱤᱥᱟᱹᱵ ᱡᱤᱣᱤᱪᱟᱹᱞᱩ [[:en:irregular heart rate|irregular heart rate]]  ᱟᱨ ᱭᱩᱨᱤᱱᱟᱨᱤ ᱨᱤᱴᱮᱱᱥᱚᱱ ᱦᱩᱭᱫᱟᱲᱮ ᱦᱟᱜᱼᱟ ।<ref name="AHFS2019" /><ref name="BNF76">{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=763|edition=76}}</ref> ᱱᱚᱣᱟ ᱵᱤᱴᱟᱼ᱓ ᱟᱰᱨᱮᱱᱡᱤᱠ ᱨᱤᱥᱮᱯᱴᱚᱨᱼᱮ ([[:en:Beta-3 adrenergic receptor|β<sub>3</sub> adrenergic receptor]]) ᱪᱮᱸᱜᱷᱟ ᱦᱚᱪᱚ ᱠᱷᱟᱹᱛᱤᱨ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ ([[:en:bladder|bladder]]) ᱚᱪᱚᱲᱚᱜᱼᱟ । <ref name="BNF76" /><ref name="AHFS2019" />

ᱰᱟᱠᱛᱚᱨᱤ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱒᱐᱑᱒ ᱥᱟᱞ ᱨᱮ ᱭᱩ ᱮᱥ ᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱟᱱᱚᱛ ᱮ ᱮᱢ ᱞᱮᱫ ᱛᱟᱦᱮᱸᱫ ।<ref>{{cite journal|last1=Sacco|first1=E|last2=Bientinesi|first2=R|display-authors=etal|date=Apr 2014|title=Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence|url=|journal=Expert Opin Drug Discov|volume=9|issue=4|pages=433–48|doi=10.1517/17460441.2014.892923|pmid=24559030}}</ref><ref name="AHFS2019">{{cite web|title=Mirabegron Monograph for Professionals|url=https://www.drugs.com/monograph/mirabegron.html|website=Drugs.com|publisher=American Society of Health-System Pharmacists|accessdate=18 March 2019|language=en}}</ref> ᱒᱐᱑᱙ ᱥᱟᱞ ᱨᱮ ᱭᱩᱱᱟᱭᱴᱮᱰ ᱠᱤᱝᱰᱚᱢᱨᱮ ([[:en:United Kingdom|United Kingdom]]) ᱮᱱᱮᱪᱮᱥ ([[:en:NHS|NHS]]) ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮᱱᱟᱜ ᱰᱳᱡ ᱯᱤᱪᱷᱟᱹ ᱒᱙ ᱯᱟᱶᱰ ᱞᱮᱠᱟ ᱠᱷᱚᱨᱚᱪ ᱦᱩᱭ ᱟᱭ ᱠᱟᱱ ᱛᱟᱦᱮᱸᱫ  ।<ref name="BNF76">{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=763|edition=76}}</ref> ᱭᱩ ᱮᱥ ᱮ ᱨᱮ ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮ ᱱᱚᱣᱟ ᱨᱮᱱᱟᱜ ᱦᱳᱞᱥᱮᱞ ᱫᱟᱢ ᱓᱖᱙ ᱟᱢᱮᱨᱤᱠᱟ ᱰᱚᱞᱟᱨ ᱠᱟᱱᱟ ।<ref name="NADAC2019">{{cite web|title=NADAC as of 2019-02-27|url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6|website=Centers for Medicare and Medicaid Services|accessdate=3 March 2019|language=en}}</ref> ᱒᱐᱑᱖ ᱥᱟᱞ ᱨᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱑ᱱᱤᱭᱩᱛ ᱠᱷᱚᱱ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱞᱮᱱ ᱠᱷᱟᱹᱛᱤᱨ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱦᱟᱠᱟᱱ ᱨᱟᱱ ᱨᱮᱱᱟᱜ ᱛᱟᱹᱞᱠᱟᱹᱨᱮ ᱒᱖᱓ ᱟᱱᱟᱜ ᱴᱷᱟᱶ ᱮ ᱟᱢᱮᱴ ᱞᱮᱫᱼᱟ ।<ref>{{cite web|title=The Top 300 of 2019|url=https://clincalc.com/DrugStats/Top300Drugs.aspx|website=clincalc.com|accessdate=22 December 2018}}</ref>

== ᱥᱟᱹᱠᱷᱭᱟᱹᱛ ==
<references group="" responsive="1"></references>

== ᱵᱟᱦᱨᱮ ᱡᱚᱱᱚᱲ ==

* Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology. 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. <nowiki>PMID 23205058</nowiki>.
[[ᱛᱷᱚᱠ:ᱨᱟᱱ]]
